Exelixis Announces Webcasts of June Investor Conference Presentations

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (NASDAQ:EXEL) will present at the following investor conferences this month:

  • Jefferies Global Healthcare Conference: Gisela Schwab, MD, the company’s executive vice president and chief medical officer, will present at 12:30 p.m. EDT / 9:30 a.m. PDT on Thursday, June 9, in New York.
  • Goldman Sachs Healthcare Conference: Michael Morrissey, PhD, the company’s president and chief executive officer, will present at 1:40 p.m. EDT / 10:40 a.m. PDT on Thursday, June 9, in Palos Verdes, California.

During their respective presentations, Dr. Schwab and Dr. Morrissey will review the most recent publicly available data for cabozantinib in castration-resistant prostate cancer, ovarian cancer, and other tumor types, as presented at the 2011 ASCO Annual Meeting (June 3-7, Chicago). They will also discuss the pivotal trial plans and regulatory strategy for cabozantinib, and provide a general business update.

Both presentations will be webcast and may be accessed via the Event Calendar page under Investors at www.exelixis.com.

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer. Exelixis is focusing its resources and development efforts exclusively on cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs. For more information, please visit the company's web site at www.exelixis.com.

Exelixis and the Exelixis logo are registered U.S. trademarks.



CONTACT:

Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President, Investor Relations and Corporate Communications
[email protected]

KEYWORDS:   United States  North America  California  Illinois  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.